Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis

This publication has 81 references indexed in Scilit:

• Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
  Journal of Clinical Oncology, 2013
• Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
  New England Journal of Medicine, 2012
• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
  Journal of Clinical Oncology, 2012
• Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
  Annals of Oncology, 2011
• Impairment of the Programmed Cell Death-1 Pathway Increases Atherosclerotic Lesion Development and Inflammation
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
• Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
  Clinical Cancer Research, 2011
• Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
  Cancer, 2010
• A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
  Investigational New Drugs, 2010
• Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
  Journal of Clinical Oncology, 2008
• Measuring inconsistency in meta-analyses
  BMJ, 2003